The food-allergy-focused biotech Intrommune Therapeutics is announcing that it is extending the duration of the ongoing Phase 1 OMEGA clinical trial of INT301 in adults with peanut allergy. The alteration will lengthen the study duration to 48 weeks to include a maintenance period. The study duration was previously 26 weeks. The New York City–based company […]
